Momenta loses steam after 'dog days' appeals ruling in enoxaparin saga
This article was originally published in Scrip
Executive Summary
As Washington continued to sweat it out during the dog days of summer, the US Court of Appeals for the Federal Circuit on 3 August delivered a cold blow to Momenta Pharmaceuticals, declaring in a 2-1 ruling the firm is unlikely to succeed on its claim of infringement against Amphastar Pharmaceuticals and Watson Pharmaceuticals involving generic enoxaparin – lifting a preliminary injunction, permitting the latter firms to market their product in the US.